A study of over 17,604 people aged 45 and over has found that semaglutide, the active ingredient in Wegovy and Ozempic, reduced the risk of major cardiac events by 20% regardless of whether participants lose weight or the amount of weight they lose during treatment.
Ozempic Cuts Heart Disease Risk by 20% Regardless of Weight Loss